Stockscreener 앱 받기
0.3703
2.58%
-0.00985
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
Theriva Biologics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and Key Disclosures - Minichart
Theriva Biologics Reports FDA Alignment on VCN-01 Phase 3 Trial Design for Metastatic Pancreatic Cancer and Q1 2026 Financial Results - Minichart
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - The Manila Times
Theriva Biologics: Q1 Earnings Snapshot - marketscreener.com
Theriva Biologics (NYSE American: TOVX) posts Q1 loss, flags going concern risk - Stock Titan
Theriva Biologics (NYSE: TOVX) narrows Q1 loss and advances VCN-01 toward pivotal trials - Stock Titan
Theriva moves pancreatic cancer drug toward Phase 3, cash into 2027 - Stock Titan
TOVX Forecast, Price Target & Analyst Ratings | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
MSN Money - MSN
Warrant vote could unlock $8.7M for Theriva Biologics (TOVX) - Stock Titan
TOVX Stock Price, Quote & Chart | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
TOVX|Theriva Biologics Inc|Price:0.330|Chg%:-0.03 - TradingKey
Theriva Biologics (TOVX) price target decreased by 42.86% to 4.08 - MSN
Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo
Why is Theriva stock gaining Monday? - MSN
symbol__ Stock Quote Price and Forecast - CNN
TOVX Should I Buy - Intellectia AI
Press Releases about Theriva Biologics, Inc. Common Stock (NYSE:TOVX) - FinancialContent
Theriva Biologics posts 34.6% EPS beat, no revenueMeet Estimates - Cổng thông tin điện tử tỉnh Lào Cai
Theriva Biologics announces pricing of $7.5M public offering - MSN
Theriva Biologics (TOVX) Comprehensive Review | Theriva Biologics posts 34.6% EPS beat, no revenueBorrow Rate - Cổng thông tin điện tử tỉnh Lào Cai
TOVX (Theriva Biologics Inc.) posts narrower than expected Q4 2025 loss, shares rise four percent on upbeat investor sentiment.Popular Trader Picks - Cổng thông tin điện tử Tỉnh Sơn La
Trending Stocks Today | Theriva Biologics Soars 67.92% Post-Market - 富途牛牛
BIOLASE Inc (BIOL) - Minichart
Theriva Biologics (NYSE: TOVX) asks shareholders to OK 16.18M warrant shares for $8.7M - Stock Titan
$Theriva Biologics (TOVX.US)$ keep loading on each pullback - Moomoo
Theriva Biologics stock surges on AACR cancer trial data - Investing.com
Theriva Biologics (TOVX) Stock Jumps 63% After Pancreatic Cancer Trial Data Drops at AACR - MEXC Exchange
Theriva Biologics stock surges on AACR cancer trial data By Investing.com - Investing.com UK
$Theriva Biologics (TOVX.US)$ it might be a miracle - Moomoo
Is Theriva Biologics (TOVX) stock breaking out today (Investors Pile In) 2026-04-20IPO Watch - Cổng thông tin điện tử tỉnh Lào Cai
Why Is Theriva Stock Gaining Monday? - Benzinga
Theriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Data from AACR - MoneyCheck
Theriva Biologics (TOVX) Shares Soar 63% on Promising Pancreatic Cancer Trial Results - parameter.io
Theriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Trial Results - Blockonomi
$Theriva Biologics (TOVX.US)$ added more to squeeze 🤞🏼🥳 - Moomoo
Theriva Biologics Presents Positive VIRAGE Phase 2b Clinical Trial Data of VCN-01 for Metastatic Pancreatic Cancer at AACR 2026 - Minichart
Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026 - GlobeNewswire Inc.
Theriva Biologics (TOVX) Set to Present New Clinical Data at AAC - GuruFocus
$Theriva Biologics (TOVX.US)$ sell too fast wow - Moomoo
Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data - TipRanks
[8-K] Theriva Biologics, Inc. Reports Material Event - Stock Titan
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - GlobeNewswire
CEO Moves: Is Theriva Biologics Inc subject to activist investor interest2026 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Theriva Biologics, Inc. (TOVX) Files Form 8-K with SEC – Company Details and Exchange Information as of April 2026 - Minichart
Theriva Biologics to reschedule stockholder meeting after lack of quorum By Investing.com - Investing.com Australia
Theriva Biologics to reschedule stockholder meeting after lack of quorum - Investing.com
Resistance Check: Is Theriva Biologics Inc in a long term uptrend2026 Rallies & Stock Market Timing Techniques - baoquankhu1.vn
Theriva Biologics Faces Delays in Warrant Approval Meeting - TipRanks
Theriva Bi Called Special Meeting Fails to Reach Quorum; Will Re‑call Meeting to Seek Approval for 16.18M Warrant Shares - TradingView
Theriva Biologics (NYSE American: TOVX) resets vote on 16,184,560 warrant shares - Stock Titan
Aug Opening: Is Theriva Biologics Inc backed by strong institutional buyingEarnings Overview Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
0.78%
3.01%
자본화:
|
볼륨(24시간):